Bioworld Insider
As biopharma deals keep pace, M&A volumes languish
Share this episode
Biopharma deal-making activity, a closely-watched marker of industry health, remained alive and well in Q2. But whither M&A? And what’s with all those $1 billion-plus deals? Join News Editor Michael Fitzhugh and BioWorld Senior Analyst Karen Carey as they chat about the latest currents in combinations, partnerships amid the pandemic, and the rising values of up-front payments – at least for those clinical-stage companies lucky enough to make lucrative deals ahead of commercialization.
The BioWorld Insider Podcasts provides timely and focused one-on-one interviews with the same key sources typically interviewed for articles such as company founders, executives, top researchers and regulators. Topics are prioritized based on the same criteria we use when selecting news to feature in BioWorld, which for more than 30 years reports the breaking news — and provides key perspective — on hundreds of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes.
